Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

Nuvance Health · NCT03937453

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
800
US sites recruiting
1
Study start
January 19, 2018
Record last updated
April 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.

Being studied: MRI/MRCP

Conditions: Pancreatic Cancer; Pancreatic Neoplasms; Diabetes Mellitus

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age of at least 50 years.
  • DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR
  • DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR
  • Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR
  • DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR
  • Deteriorating Diabetes: DM with >2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance
  • ECOG Performance Status of 0-1.
  • No known contraindications to MRI examination or gadolinium contrast.
  • Willing to undergo MRI and screening for metal implants or metal injury.
  • Ability to provide informed consent.
  • Willing to return to study site for all study assessments.

Exclusion Criteria

  • Prior history of pancreatic cancer.
  • Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.
  • Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).
  • Hereditary pancreatitis.
  • Use of high dose glucocorticoid steroids (at least 20 mg daily of prednisone) within 3 months of diabetes diagnosis or elevation of HbA1c. Lower doses of steroid use as a cause of glucocorticoid-induced diabetes will be made on a case-by-case basis.
  • Contraindication to MRI examination or gadolinium contrast.
  • Pregnant or nursing women.
  • Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

Recruiting US locations

  • Nuvance Health

    Norwalk, CT 06856

    Site contact: Tammy Lo, MSN · 203-855-3551 · Tammy.Lo@nuvancehealth.org

Study contacts (from the official record)

  • Tammy Lo, MSN · 203-855-3551 · Tammy.Lo@nuvancehealth.org
  • Pramila Krumholtz, MSN · 203-739-7997 · Pramila.Krumholtz@nuvancehealth.org
All diabetes studies in Connecticut →
A Pancreatic Cancer Screening Study in Individuals With New-Onset… (NCT03937453) | Bored Studies